In 2024, SIA GriPharma had revenue of 384.2 thousand EUR and loss of 162.1 thousand EUR. The company has 3 employees. Beneficial owners: Aleksandrs Mežeckis, Andrejs Škarupins.
| year | 2024Latest | 2023 | 2022 |
|---|---|---|---|
Revenue | 384,2k € -40.6% | 647,3k € +65.7% | 390,7k € +86.4% |
Profit | -162,1k € -637.8% | 30,1k € -59.0% | 73,5k € +52.3% |
Assets | 124,1k € -58.3% | 297,6k € +17.9% | 252,4k € +89.1% |
Liabilities | 126,8k € +20.4% | 105,3k € +16.7% | 90,3k € +101.1% |
Equity | -2,7k € -101.4% | 192,3k € +18.6% | 162,1k € +83.0% |
Employees | 3 +0.0% | 3 +0.0% | 3 +50.0% |
Overall rating | C+61/100 |
Financial health | 15/100 |
Credit history | 100/100 |
Legal history | 100/100 |
Business activity | 35/100 |
| Overall risk | Medium |
No risk flags | |
No tax debts | |
Negative profit | |
Regular report filing | |
| Name, surname | Birth date | Position | Representation rights | Registered | |
|---|---|---|---|---|---|
| Board member | Independently |
| Name | Changed |
|---|---|
| SIA Nordic Pharm | 23 September 2015 |
| SIA Nordic Pharm | 23 September 2015 |
| SIA Nordic Pharm | 23 September 2015 |
| SIA Nordic Pharm | 23 September 2015 |
| SIA Nordic Pharm | 23 September 2015 |
| SIA Nordic Pharm | 23 September 2015 |
| SIA Nordic Pharm | 23 September 2015 |
| SIA Nordic Pharm | 23 September 2015 |
| SIA Nordic Pharm | 23 September 2015 |
| SIA Nordic Pharm | 23 September 2015 |
| SIA Nordic Pharm | 23 September 2015 |
| SIA Nordic Pharm | 23 September 2015 |
| SIA Nordic Pharm | 23 September 2015 |
| SIA Nordic Pharm | 23 September 2015 |
| SIA Nordic Pharm | 23 September 2015 |
| SIA Nordic Pharm | 23 September 2015 |
| SIA Nordic Pharm | 23 September 2015 |
| SIA Nordic Pharm | 23 September 2015 |
| SIA Nordic Pharm | 23 September 2015 |
| SIA Nordic Pharm | 23 September 2015 |
Project count
48
Total funding
€87 420 187
EU support
€50 000 000
| Project | Period | Role | Funding received | Status |
|---|---|---|---|---|
Inovatīvu produktu un tehnoloģiju izstrāde Farmācijas, biomedicīnas un medicīnas tehnoloģiju kompetences centra ietvaros 1.2.1.2.i.2/1/24/A/CFLA/005 Program: AF | 2024. gada 2. jūlijs until 2027. gada 31. decembris | partner | - | Līgums |
Inovatīvu produktu un tehnoloģiju izstrāde Farmācijas, biomedicīnas un medicīnas tehnoloģiju kompetences centra ietvaros 1.2.1.2.i.2/1/24/A/CFLA/005 Program: AF | 2024. gada 2. jūlijs until 2027. gada 31. decembris | partner | - | Līgums |
Inovatīvu produktu un tehnoloģiju izstrāde Farmācijas, biomedicīnas un medicīnas tehnoloģiju kompetences centra ietvaros 1.2.1.2.i.2/1/24/A/CFLA/005 Program: AF | 2024. gada 2. jūlijs until 2027. gada 31. decembris | partner | - | Līgums |
Inovatīvu produktu un tehnoloģiju izstrāde Farmācijas, biomedicīnas un medicīnas tehnoloģiju kompetences centra ietvaros 1.2.1.2.i.2/1/24/A/CFLA/005 Program: AF | 2024. gada 2. jūlijs until 2027. gada 31. decembris | partner | - | Līgums |
Inovatīvu produktu un tehnoloģiju izstrāde Farmācijas, biomedicīnas un medicīnas tehnoloģiju kompetences centra ietvaros 1.2.1.2.i.2/1/24/A/CFLA/005 Program: AF | 2024. gada 2. jūlijs until 2027. gada 31. decembris | partner | - | Līgums |
Inovatīvu produktu un tehnoloģiju izstrāde Farmācijas, biomedicīnas un medicīnas tehnoloģiju kompetences centra ietvaros 1.2.1.2.i.2/1/24/A/CFLA/005 Program: AF | 2024. gada 2. jūlijs until 2027. gada 31. decembris | partner | - | Līgums |
Inovatīvu produktu un tehnoloģiju izstrāde Farmācijas, biomedicīnas un medicīnas tehnoloģiju kompetences centra ietvaros 1.2.1.2.i.2/1/24/A/CFLA/005 Program: AF | 2024. gada 2. jūlijs until 2027. gada 31. decembris | partner | - | Līgums |
Inovatīvu produktu un tehnoloģiju izstrāde Farmācijas, biomedicīnas un medicīnas tehnoloģiju kompetences centra ietvaros 1.2.1.2.i.2/1/24/A/CFLA/005 Program: AF | 2024. gada 2. jūlijs until 2027. gada 31. decembris | partner | - | Līgums |
Inovatīvu produktu un tehnoloģiju izstrāde Farmācijas, biomedicīnas un medicīnas tehnoloģiju kompetences centra ietvaros 1.2.1.2.i.2/1/24/A/CFLA/005 Program: AF | 2024. gada 2. jūlijs until 2027. gada 31. decembris | partner | - | Līgums |
Inovatīvu produktu un tehnoloģiju izstrāde Farmācijas, biomedicīnas un medicīnas tehnoloģiju kompetences centra ietvaros 1.2.1.2.i.2/1/24/A/CFLA/005 Program: AF | 2024. gada 2. jūlijs until 2027. gada 31. decembris | partner | - | Līgums |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
SIA GriPharma is located at Rīga, Lizuma iela 1 k-12, LV-1006.
In 2024, SIA GriPharma had revenue of 384 161 EUR and loss of 162 113 EUR. Compared to previous year, revenue decreased by 40.6%. View full financial report →
In 2024, SIA GriPharma had an average of 3 employees. View tax history →
The beneficial owners of SIA GriPharma are Aleksandrs Mežeckis and Andrejs Škarupins. View ownership details →
Yes, SIA GriPharma is registered as an active VAT payer with VAT number LV50103904871.
In 2024, the average gross salary at SIA GriPharma was approximately 995,73 € per month (net ~ 793,98 €). This is an approximate calculation. View salary details →
SIA GriPharma was founded on June 4, 2015. The company has been operating for 11 years.
| Indicator | Value | Rank | Comparison | |
|---|---|---|---|---|
Company age | 11 years | 103 - 107 | 50% | |
Net revenue | 384 161,00 € | 17 - 21 | 90% | |
Profit | -162 113,00 € | 195 - 199 | 6% | |
Equity | -2707,00 € | - | 10% | |
Assets | 124 107,00 € | 77 - 81 | 61% | |
Fixed assets | 42 875,00 € | - | 90% | |
Liquidity | 2.73 | - | 75% | |
Profitability | -42.2% | - | 10% | |
Registered capital | 3000,00 € | - | 25% |
Annual financial report for 2024.
Annual financial report for 2023.
Annual financial report for 2022.
Annual financial report for 2021.
Annual financial report for 2020.
Annual financial report for 2019.
Registered in the Latvian company register.
| Name, surname | Birth date | Shares | Ownership rights | |
|---|---|---|---|---|
| Aleksandrs Mežeckis | 1800 | 60.00% | ||
| Andrejs Škarupins | 1200 | 40.00% |
| Name, surname | Nationality | Birth date | |
|---|---|---|---|
| Aleksandrs Mežeckis | LV | ||
| Andrejs Škarupins | LV |